Ridhima Goel

About

I am a cancer biology researcher with over six years of experience in translational oncology, currently completing my PhD at All India Institute of Medical Sciences, New Delhi, with prior research training at Indian Institute of Science. My work focuses on identifying novel therapeutic targets in ovarian cancer, evaluating small-molecule inhibitors, and developing nanotechnology-assisted targeted drug delivery systems for precision oncology. I am currently seeking opportunities in the biotechnology and pharmaceutical industry for roles such as Research Scientist, Scientist – Cancer Biology, Translational Research Scientist, Drug Discovery Scientist, Nanomedicine Scientist, or Oncology Research Associate, as well as opportunities in medical writing, scientific editing, and research communication.

Employment

• All India Institute of Medical Sciences Senior Research Fellow
  2022 - 2024
• All India Institute of Medical Sciences Junior Research Fellow
  2020 - 2022
• Indian Institute of Science Bangalore Junior Research Fellow
  2017 - 2019

Education

• All India Institute of Medical Sciences PhD
  2020 - Present
• University of Delhi M.Sc
  2015 - 2017
• University of Delhi B.Sc
  2012 - 2015

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Targeted paclitaxel delivery in ovarian cancer via AP1-functionalized elastin-like polypeptide nanocarriers: development and characterization
  BMC Cancer 2026 1 citation DOI: 10.1186/S12885-026-15615-0
  +Save
• Applications of Organoids and Spheroids in Anaplastic and Papillary Thyroid Cancer Research: A Comprehensive Review
  Organoids 2025 2 citations DOI: 10.3390/organoids4030018
  +Save
• Overcoming paclitaxel resistance in ovarian cancer cells using DN200434, an inverse agonist of estrogen-related receptor gamma (ERRγ)
  Biochemical and Biophysical Research Communications 2025 0 citations DOI: 10.1016/J.BBRC.2025.152351
  +Save
• Synthesis and characterization of IL-4R ligand mimic (AP1)-functionalized elastin-like polypeptide-based nanopolymers as selective delivery vehicles for paclitaxel in ovarian cancer
  Cancer Research 2025 0 citations DOI: 10.1158/1538-7445.AM2025-6893
  +Save
• An Overview of the Cancer Targeting Attributes of the Elastin Like Polypeptide Nano-Carriers: Discerning Active and Passive Modes
  Advanced Therapeutics 2024 3 citations DOI: 10.1002/ADTP.202400332
  +Save
• Estrogen-Related Receptor Gamma (ERRγ) as Biomarker and Novel Target for Therapeutic Intervention on Cancer: A Review
  Advanced Therapeutics 2024 1 citation DOI: 10.1002/ADTP.202400192
  +Save
• Investigating the potential of estrogen-related receptor gamma (ERRg) in colorectal cancer and examining the therapeutic implications of DN200434 (ERRg inverse agonist) & MK2206 (Akt inhibitor)
  Annals of Oncology 2024 0 citations DOI: 10.1016/J.ANNONC.2024.05.164
  +Save
• Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine
  Discover Oncology 2024 12 citations DOI: 10.1007/S12672-024-01677-8
  +Save
• Unsung versatility of elastin-like polypeptide inspired spheroid fabrication: A review
  International Journal of Biological Macromolecules 2023 15 citations DOI: 10.1016/j.ijbiomac.2023.123664
  +Save
• Unfolding of Imminent Bio-Signatures in the Prognosis of Thyroid Cancer; The Emergence of Estrogen Related Receptor Gamma (ERRγ) as a Hurricane
  Asian Pacific Journal of Cancer Prevention 2023 6 citations DOI: 10.31557/apjcp.2023.24.2.375
  +Save